Navigation Links
DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3)

60760258

A replay of the webcast will be available through May 17, 2007 and may be accessed by dialing 1-888-286-8010. International callers should dial 617-801-6888. The replay passcode for all callers is 25344900. The webcast will be archived on the Dyax website for an indefinite period of time.

About Dyax

Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development.

Dyax's lead product candidate is DX-88, a recombinant small protein that is currently in clinical trials for its therapeutic potential in two separate indications. Dyax has successfully completed three Phase 2 trials and a Phase 3 trial of DX-88 for the treatment of hereditary angioedema (HAE). A confirmatory study, known as EDEMA4, is planned and expected to begin in the first quarter of 2007. DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S. for the treatment of acute attacks of HAE.

Additionally, Dyax has successfully completed a Phase 1/2 trial of DX-88 for the prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures. Dyax is initiating a Phase 2 trial for further development of DX-88 in on-pump cardiothoracic surgery (CTS), including CABG and heart valve replacement or repair procedures.

Dyax identified DX-88 and other compounds in its pipeline using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue-generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents.

Dyax is headquartered in Cambridge, Massachusett
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
3. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
7. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
8. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
Post Your Comments:
(Date:9/19/2014)... 19, 2014 /PRNewswire-iReach/ -- "United States ... provides key market data on the ... The report provides value, in millions ... units) within market categories – Bronchoscopes, ... & Gastroscopes, Duodenoscopes, Laparoscopes, Hysteroscopes, Sinuscopes, ...
(Date:9/19/2014)... According to the new ... therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, ... Global Forecast to 2019" published by MarketsandMarkets, the global ... Million by 2019 from $14,240.0 Million in 2014, ... 2019. Browse 74 market data tables ...
(Date:9/19/2014)... Sept. 19, 2014 Merck (NYSE: MRK ), ... and Canada , is teaming with celebrity chef ... Logra Tus Metas , an educational program encouraging Hispanics with type ... a key treatment goal to help reduce the risk of serious ... are at a higher risk for developing type 2 diabetes than ...
Breaking Medicine Technology:United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5
(Date:9/20/2014)... Angeles, CA (PRWEB) September 20, 2014 ... score of 3.1 out of 5, indicating a moderately ... firm IBISWorld, this score reflects current and future pricing ... from historically high prices. Other factors that negatively affect ... in demand for construction and the moderate switching costs. ...
(Date:9/20/2014)... California (PRWEB) September 20, 2014 Final ... have announced the release of the Information theme for FCPX ... would use to describe the Information theme,” says Christina Austin, ... easy to look so professional.” , Information features easy to ... the parameters of the environment. Change the background color, color ...
(Date:9/20/2014)... September 20, 2014 MarijuanaDoctors.com recently ... showing at the PAIN Week conference that was ... and Casino in Las Vegas from September 2nd ... attended PAIN Week in the hopes of educating ... viable and legitimate tool to treat chronic Pain, ...
(Date:9/19/2014)... “Copay coupons,” a drug manufacturer marketing ... among patients with prescription drug coverage, may now be ... report from the Department of Health and Human ... laws prohibit suppliers from offering side-payments to increase sales ... , The report highlights that two recent surveys, including ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- As kids transition ... targets of cyberbullies, according to a recent study. ... 5 through 8 found that verbal and physical bullying ... vary, bullying intervention and prevention strategies must address all ... among boys and girls, the researchers said. The study ...
Breaking Medicine News(10 mins):Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2
... Safety Initiatives, DUBLIN, Ohio, Dec. 3 ... participating in the Institute for Healthcare,Improvement,s (IHI) 5 ... it is granting $537,000 to 37 hospitals that,enroll ... receive an average of,$15,000 each to help deepen ...
... COMPOUNDERS; ENABLES CONVENIENT, SECURE, VIRTUALLY ... OF CLASS II CONTROLLED SUBSTANCES, LAKE FOREST, ... provider of outsourced hospital compounded sterile preparations,announced a ... entire line of Schedule II Controlled Substances.,The initiative ...
... equipment, survey finds , , MONDAY, Dec. 3 (HealthDay News) -- ... nearest emergency room might want to keep a new finding ... United States have all the equipment they should have on ... to the survey, however, so the UCLA researchers suspect the ...
... income families and,uninsured individuals everywhere now have access ... prescription per month with delivery to their,home or ... new prescription assistance service,to those who qualify. It ... coverage, according to Doug Pierce, founder of the ...
... C-section has hit number one for,inpatient surgery in the ... Scarring, swelling, tenderness and surgical recovery are a,reality for ... Cesarean Underwear(TM) attempts to address the needs,of Cesarean moms ... of a C-section in mind. See http://www.cpanty.com ., ...
... Misys plc (FTSE: MSY.L),the global application software and services ... its Equation and Trade Innovation,solutions to support its expansion ... installed in its Hong Kong location since,2003, and have ... and,business for the bank. UCB concluded to expand the ...
Cached Medicine News:Health News:Cardinal Health Foundation Grants $537,000 to Rural, Public Hospitals in Support of IHI'S 5 Million Lives Campaign 2Health News:Cardinal Health Foundation Grants $537,000 to Rural, Public Hospitals in Support of IHI'S 5 Million Lives Campaign 3Health News:Cardinal Health Foundation Grants $537,000 to Rural, Public Hospitals in Support of IHI'S 5 Million Lives Campaign 4Health News:PharMEDium Announces Electronic 222 Ordering Initiative 2Health News:Most ERs Not Fully Prepared for Pediatric Patients 2Health News:Most ERs Not Fully Prepared for Pediatric Patients 3Health News:$7 Brand Name Prescriptions for Low Income and Un-Insured Avoid Prescription Discount Cards! 2Health News:Finally, Easy After-Cesarean Care for the 1.3 Million C-Section Moms 2Health News:United Commercial Bank Extends its Use of Misys' Equation and Trade Innovation Systems to Support its Expansion in Taiwan 2Health News:United Commercial Bank Extends its Use of Misys' Equation and Trade Innovation Systems to Support its Expansion in Taiwan 3
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
... Vivid i is the worlds ... high-performance, full-featured imaging in a lightweight design. ... addresses one of the biggest challenges in ... diagnostic information. The new system expands the ...
The Bio-Quant CK-MB test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of,CK-MB in human serum specimens as an aid in the diagnosis of myocar...
... with a diseased heart, the only therapy solution open ... However, donor organs are not always readily available. For ... on the waiting list for a donor organ. , ... the life of a patient. On the one hand, ...
Medicine Products: